Acclerys Stock Climbs 6 Percent After Analyst Begins Coverage, Lauds Firm s Clean Balance Sheet

Mar 14, 2005

NEW YORK, March 14 (GenomeWeb News) - Shares in Accelrys were up 6 percent, or $.30, at $5.30 in mid-afternoon trading after a securities analyst began covering the company today and gave the stock a 'Buy' rating.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Marks Left on the Genome

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

Cost and Coverage of Gene Therapies

The Wall Street Journal looks into the cost of new gene therapies.

Mosquito Population Crash

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

This Week in PNAS

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.

Main menu